Evogene Announces Filing of Annual Report on Form 20-F
Evogene Ltd. (Nasdaq: EVGN) has filed its Annual Report on Form 20-F for the fiscal year ending December 31, 2022, with the Securities and Exchange Commission. The report can be accessed on the company's investor relations website and the SEC's site. Evogene specializes in computational biology, utilizing big data and AI to innovate product development across life sciences. The firm operates three tech-engines: MicroBoost AI, ChemPass AI, and GeneRator AI, focusing on product development in microbes, small molecules, and genetic elements, respectively, through its five subsidiaries.
- Filed Annual Report on Form 20-F, demonstrating compliance with SEC regulations.
- Focus on leveraging AI to enhance product development efficiency and success rates.
- None.
REHOVOT, Israel, March 30, 2023 /PRNewswire/ -- Evogene Ltd. (Nasdaq: EVGN) (TASE: EVGN), a leading computational biology company focused on revolutionizing product discovery and development in multiple life-science based industries, today announced that it filed its Annual Report on Form 20-F for the fiscal year ended December 31, 2022 with the Securities and Exchange Commission.
The Annual Report on Form 20-F can be accessed on the Company's investor relations website https://evogene.com/investor-relations/ and on the SEC's website at http://www.sec.gov. The Company's security holders may request a hard copy of the Annual Report free of charge by visiting the Contact Us page of the Company's website.
About Evogene Ltd.
Evogene Ltd. (Nasdaq: EVGN, TASE: EVGN) is a computational biology company leveraging big data and artificial intelligence, aiming to revolutionize the development of life-science based products by utilizing cutting-edge technologies to increase the probability of success while reducing development time and cost.
Evogene established three unique tech-engines - MicroBoost AI, ChemPass AI and GeneRator AI. Each tech-engine is focused on the discovery and development of products based on one of the following core components: microbes (MicroBoost AI), small molecules (ChemPass AI), and genetic elements (GeneRator AI).
Evogene uses its tech-engines to develop products through strategic partnerships and collaborations, and its five subsidiaries including:
- Biomica Ltd. (www.biomicamed.com) developing and advancing novel microbiome-based therapeutics to treat human disorders powered by MicroBoost AI;
- Lavie Bio Ltd. (www.lavie-bio.com) - developing and commercially advancing, microbiome based ag-biologicals powered by MicroBoost AI;
- AgPlenus Ltd. (www.agplenus.com) -developing next generation ag chemicals for effective and sustainable crop protection powered by ChemPass AI;
- Canonic Ltd. (www.canonicbio.com) – developing medical cannabis products based on decoding plant genetics for optimized therapeutic effect powered by GeneRator AI; and
- Casterra Ag Ltd. (www.casterra.co)– developing and marketing superior castor seed varieties producing high yield and high-grade oil content, on an industrial scale for the biofuel and other industries powered by GeneRator AI.
Investor Relations Contact |
Kenny Green T: +1 212 378 8040
|
View original content:https://www.prnewswire.com/news-releases/evogene-announces-filing-of-annual-report-on-form-20-f-301786247.html
SOURCE Evogene
FAQ
What is the significance of Evogene's Annual Report on Form 20-F filed on March 30, 2023?
Where can I access Evogene's Annual Report for the fiscal year ended December 31, 2022?
What technologies does Evogene use for product development?
What are Evogene's main business areas?
